Product Naming

The most-recognized brands.

The most-recognized anti-infective brand name in North America is Cipro. This pharmaceutical brand name was most recognized by 14.6% of physicians in a study done by Brand Institute, Inc., a biotechnology branding, pharmaceutical branding, and consumer branding consultancy firm. First approved in October 1987, Cipro, composed of ciprofloxacin, is indicated for the treatment of pyelonephritis, complicated urinary tract infections in pediatric patients 1 year old to 17 years old, the reduction of the incidence or progression of disease following exposure to anthrax, empirical therapy for febrile nrutropenia patients 1 year old or older, acute sinusitis, mild-to-moderate bone and joint infections, lower respiratory tract infections, acute exacerbations of chronic bronchitis, acute uncomplicated cystitis in females, complicated intra-abdominal infections, skin and skin structure infections, bone and joint infections, typhoid fever, uncomplicated cervical and urethral gonorrhea, infectious diarrhea, chronic bacterial prostatitis, mild-to-moderate and severe nosocomila pneumonia, and acute uncomplicated pyelonephritis. Bayer Pharmaceutical Corp. (www.bayerpharma.com) developed Cipro, which is marketed by Schering-Plough Corp (www.sgp.com).

The second most-recognized pharmaceutical brand name in North America is Zithromax, which was most recognized by 12.6% of physicians surveyed. Zithromax is indicated for the treatment of disseminated Mycobacterium avium complex infections in persons with advanced HIV infection in combination with ethambutol, mid-to-moderate acute bacterial exacerbation of chronic obstructive pulmonary disease, pediatric acute otitis media, community-acquired pneumonia, pharyngitis/tonsillitis, mild-t-moderate uncomplicated skin and skin structure infections, urethritis and cervicitis, chancroid in males, genital ulcer disease in men, acute bacterial sinusitis, and the prophylaxis of Mycobacterium avium complex infections in HIV patients. Composed in azithromycin, Zithromax is marketed by Pfizer Inc. (www.pfizer.com) and was first approved in November 1991.

Levaquin is the third most-recognized anti-infective brand name in North America. About 11.8% of physicians most recognized Levaquin, which was first approved in December 1996. Levaquin, which contains levofloxacin, is approved for the treatment of community-acquired pneumonia, acute maxillary sinusitis, complicated urinary tract infections, uncomplicated skin and skin structure infections, uncomplicated urinary tract infections, acute pelonephritis, acute bacterial exacerbation of chronic bronchitis, the short-course treatment of mild-to-server community-acquired pneumonia, hospital-acquired pneumonia, chronic bacterial prostatitis, and for the short-course treatment of mild-to-severe community-acquired pneumonia. Ortho-McNeil Pharmaceutical Inc. (www.ortho-mcneil.com) markets Levaquin.
Product Naming

Product Naming

In Europe, the top two pharmaceutical brand names are marketed by GlaxoSmithKline (www.gsk.com) and are used to treat common infections. The most-recognized anti-infective brand name is Augmentin. About 13% of physicians recognized Augmentin the most.

Amoxil is the second most-recognized anti-infective brand, with 9.8% of physicians recognizing the brand name the most. Both medicines are composed of amoxicillin and are indicated for the treatment of bacterial infections.

The third-most recognized brand is Ciproxin. About 7.1% of physicians recognize the pharma name brand the most. Composed of ciprofloxacin, Ciproxin, is indicated for the treatment of bacterial infections and is marketed by Bayer.

Brand Institute Inc. (www.brandinstitute.com), a consumer, biotech and pharmaceutical brand naming consulting company, surveyed more than 2,000 physicians and hospital and retail pharmacists in North America and Europe to determine the most-recognizable brands in the category of anti-infectives. Brandpoll is a marketing tool designed to help clients monitor the competitive marketplace and identify the potential strengths and weaknesses of their brands.
Product Naming